Abu Dhabi Introduces WINREVAIR: A Major Breakthrough in Pulmonary Arterial Hypertension Treatment
The Department of Health – Abu Dhabi (DoH) has announced the introduction of WINREVAIR for Pulmonary Arterial Hypertension (PAH). Developed by MSD, this innovative treatment is a significant step forward for this severe condition in the Emirate.
Medication Details
WINREVAIR is administered via subcutaneous injection every three weeks in specific doses. It can be self-administered by patients or caregivers under supervision.
Mechanism and Benefits
WINREVAIR targets signaling pathways that cause excessive cell proliferation in pulmonary blood vessels. This reduces vascular narrowing, improves blood flow, and eases cardiovascular strain. Clinical studies show it reduces the risk of clinical worsening events by 84%. It also improves exercise capacity and reduces pulmonary vascular resistance.
Approval and Availability
WINREVAIR has received approval from both the FDA and the EMA. The first batch arrived in Abu Dhabi this month, making the Emirate the first in the region to offer it.
Impact on Patients
Pulmonary Arterial Hypertension is a severe condition that affects the arteries in the lungs, leading to increased pressure in the pulmonary blood vessels. It can cause narrowed, blocked, or damaged pulmonary vessels, resulting in reduced blood flow and excessive strain on the heart, ultimately leading to heart failure.
WINREVAIR significantly improves patient care and healthcare outcomes for individuals with PAH. Studies suggest it may extend patients’ average life expectancy by over ten years when combined with current standard therapies.
Demographics and Prevalence
PAH affects between 15 to 60 people per million globally, with the majority being women, who comprise 70% to 80% of cases. Individuals aged 50 to 65 experience the highest prevalence of this condition.
Statements and Partnerships
Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, emphasized Abu Dhabi’s commitment to providing advanced and innovative treatments. This reinforces the Emirate’s position as a global healthcare leader. Ashraf Mallak, Managing Director of MSD GCC, expressed enthusiasm for collaborating with DoH to provide early access to WINREVAIR. He highlighted the importance of this partnership in enhancing healthcare outcomes in the region.
Overall, the introduction of WINREVAIR marks a significant advancement in the treatment of Pulmonary Arterial Hypertension, offering improved outcomes and enhanced life expectancy for patients in Abu Dhabi. The impact of WINREVAIR on patient health is likely to be profound, highlighting the importance of innovative therapies in today’s healthcare landscape.
